<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676217</url>
  </required_header>
  <id_info>
    <org_study_id>1917</org_study_id>
    <nct_id>NCT04676217</nct_id>
  </id_info>
  <brief_title>Position Related Changes in Macular Hole Morphology Before and After Surgery</brief_title>
  <official_title>Position Related Changes in Macular Hole Morphology Before and After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse-Bergen HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular hole is a full thickness retinal defect in the very centre of the retina that gives&#xD;
      the sharpest vision. The condition causes a substantial deterioration of visual acuity, and&#xD;
      operative measures are necessary in order to close the defect and improve the visual&#xD;
      function. A macular hole has varying degrees of retinal oedema surrounding the hole edges.&#xD;
      The oedema is maintained by continuous of liquid into the tissue and effectively prevents&#xD;
      spontaneous closure. For that reason it is essential for macular hole closure that the macula&#xD;
      has minimal contact with intraocular fluid in the very early postoperative phase. This is why&#xD;
      the treatment included a long-lasting intraocular gas tamponade and typically, one week of&#xD;
      face-down positioning (FDP) after surgery.Our aim is to investigate the impact of diurnal,&#xD;
      orthostatic, and gravitational variations on macular hole morphology before and after&#xD;
      surgery. The participants will be examinated with optical coherence tomography 8-10 am, 1 pm,&#xD;
      and 3 pm. Between 8 am and 1 pm ,the patient is encouraged to an upright position. After the&#xD;
      1 pm examination, the patient will be positioned flat on the side of the eye with macular&#xD;
      hole until the 3 pm examination. The surgery will be performed before 10 am. Postoperatively&#xD;
      a randomization to face down positioning or no positioning until 3 am. Optical coherence&#xD;
      tomography images through gas tamponade is made at 3 am.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular hole mid diameter</measure>
    <time_frame>1 day</time_frame>
    <description>Micrometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular hole basal diameter</measure>
    <time_frame>1 day</time_frame>
    <description>Micrometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular hole mid area</measure>
    <time_frame>1 day</time_frame>
    <description>Square micrometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>1 day</time_frame>
    <description>Micrometer</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Macular Holes</condition>
  <arm_group>
    <arm_group_label>FDP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Face down positioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No positioning named &quot;non-supine positioning&quot;. Participants are to avoid recumbent positioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postoperative positioning advice</intervention_name>
    <description>The postoperative positioning advice until 3 am the same day.</description>
    <arm_group_label>FDP</arm_group_label>
    <arm_group_label>NSP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary macular hole&#xD;
&#xD;
          -  Able to sign informed consent&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vitreoretinal surgery in the study eye&#xD;
&#xD;
          -  Secondary macular holes caused by other conditions than vitreomacular traction&#xD;
&#xD;
          -  Myopic macular hole, i.e. excessive myopia (more than -6 dioptres)&#xD;
&#xD;
          -  Posttraumatic macular hole&#xD;
&#xD;
          -  Macular holes secondary to retinal detachment or other retinal diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vegard Forsaa, MD, PhD</last_name>
    <phone>004748152212</phone>
    <email>forsaa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birger Lindtjoern, MD</last_name>
    <phone>004795826869</phone>
    <email>birgerl@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joergen Krohn, PhD</last_name>
      <email>jorgen.krohn@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Joergen Krohn, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paal Varhaug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital, Department of Ophthalmology</name>
      <address>
        <city>Stavanger</city>
        <zip>4016</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vegard Forsaa, MD</last_name>
      <phone>+47 48152212</phone>
      <email>vegard.forsaa@sus.no</email>
    </contact>
    <investigator>
      <last_name>Vegard Forsaa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Birger Lindtj√∏rn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

